<DOC>
	<DOCNO>NCT01656642</DOCNO>
	<brief_summary>This open-label , multicenter , Phase Ib , dose-escalation cohort-expansion study atezolizumab ( anti-PD-L1 antibody ) combination vemurafenib vemurafenib plus cobimetinib participant BRAFV600-mutation positive metastatic melanoma . Enrolled participant may continue treatment longer experience clinical benefit assess investigator alignment protocol .</brief_summary>
	<brief_title>A Phase 1b Study Atezolizumab Combination With Vemurafenib Vemurafenib Plus Cobimetinib Participants With BRAFV600-Mutation Positive Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologic cytologic documentation metastatic Stage IIIc unresectable melanoma , BRAFV600 mutation assess BRAF V600 Mutation Test . Origin primary tumor may skin , mucosal , acral location uveal origin . Participants unknown primary tumor may eligible uveal melanoma rule Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic end organ function Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) Version 1.1 For woman childbearing potential , agreement remain abstinent ( refrain heterosexual intercourse ) use 2 effective form contraceptive method include least 1 result failure rate less ( &lt; ) 1 percent ( % ) per year treatment period least 6 month last dose study drug For men , agreement remain abstinent ( refrain heterosexual intercourse ) use 2 contraceptive measure , agreement refrain donate sperm Agreement mandatory archival tissue fresh biopsy Agreement collection serial fresh lesion sample ( require , feasible , entry Escalation Cohorts 4 expansion cohort optional , encouraged Escalation Cohorts 2 &amp; 3 ) Receipt prior systemic anticancer therapy unresectable , locally advanced metastatic melanoma Receipt prior immunomodulatory agent , include program death1 ( PD ) 1 programmed deathligand 1 ( PDL1 ) target therapy cytotoxic Tlymphocyteassociated antigen 4 ( CTLA4 ) target therapy , include ipilimumab ( exclusion criterion apply patient enrolled Expansion Cohort A ) Receipt prior mitogenactivated protein kinase ( MAPK ) inhibitor pathway agent , include mitogenactivated protein kinase ( MEK ) kinase inhibitor BRAF kinase inhibitor Major surgical procedure within 28 day prior Day 1 anticipation need major surgical procedure course study Radiotherapy le equal ( &lt; = ) 7 day prior Day 1 Adverse event prior anticancer therapy resolve Grade &lt; = 1 except alopecia Any active malignancy ( BRAFmutated melanoma ) previous malignancy within past 3 year For participant enrol vemurafenib+cobimetinib+ atezolizumab cohort : history evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment/central serous chorioretinopathy , retinal vein occlusion , neovascular macular degeneration Pregnant breastfeed woman Intake St. John 's wort hyperforin ( potent cytochrome P450 CYP3A4 enzyme inducer ) grapefruit juice ( potent cytochrome P450 CYP3A4 enzyme inhibitor ) within 7 day prior initiation study treatment Known hypersensitivity biopharmaceuticals produce Chinese hamster ovary cell component atezolizumab formulation know hypersensitivity component cobimetinib vemurafenib Inability comply study followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PD-L1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>antiPD-L1</keyword>
	<keyword>MPDL3280A</keyword>
	<keyword>Melanoma</keyword>
	<keyword>BRAF</keyword>
	<keyword>MPDL320A</keyword>
</DOC>